Acasti Pharma Other Non-Current Liabilities 2014-2024 | ACST
Acasti Pharma other non-current liabilities from 2014 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Acasti Pharma Annual Other Non-Current Liabilities
(Millions of US $) |
| 2024 |
$4 |
| 2023 |
$ |
| 2022 |
$0 |
| 2021 |
$5 |
| 2020 |
$2 |
| 2019 |
$12 |
| 2018 |
$5 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$2 |
| 2015 |
$ |
| 2014 |
$11 |
| 2014 |
$ |
| 2013 |
$ |
| 2013 |
$ |
Acasti Pharma Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$3 |
| 2024-03-31 |
$4 |
| 2023-12-31 |
$3 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
$0 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$5 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$2 |
| 2019-12-31 |
$23 |
| 2019-09-30 |
$18 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$12 |
| 2018-12-31 |
$10 |
| 2018-09-30 |
$15 |
| 2018-06-30 |
$6 |
| 2018-03-31 |
$5 |
| 2017-12-31 |
$4 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-02-28 |
$0 |
| 2016-11-30 |
$0 |
| 2016-08-31 |
$0 |
| 2016-05-31 |
$0 |
| 2016-03-31 |
$0 |
| 2016-02-29 |
|
| 2015-12-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$1 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
$1 |
| 2014-09-30 |
$6 |
| 2014-06-30 |
$6 |
| 2014-03-31 |
$11 |
| 2014-02-28 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.028B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
